Tianjiao Pei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tianjiao Pei has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jiayu Liang
Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
1 shared publication Junjie Zhao
Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
1 shared publicationYang Yang
Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
1 shared publicationYu Shen
Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
1 shared publicationYuyang Xia
Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
1 shared publicationZilin Wang
Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 14 February 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-13
Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer
Long noncoding RNAs (lncRNAs) are a group of noncoding RNAs with transcript lengths of >200 nucleotides. Mounting evidence suggests that lncRNAs are closely associated with tumorigenesis. LncRNA H19 (H19) was the first lncRNA to function as an oncogene in many malignant tumors. Apart from the established role of H19 in promoting cell growth, proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and metastasis, it has been recently discovered that H19 also inhibits programmed cell death (PCD) of cancer cells. In this review, we summarize the mechanisms by which H19 regulates PCD in cancer cells through various signaling pathways, molecular mechanisms, and epigenetic modifications. H19 regulates PCD through the Wnt/β-catenin pathway and the PI3K–Akt–mTOR pathway. It also acts as a competitive endogenous RNA (ceRNA) in PCD regulation. The interaction between H19 and RNA-binding proteins (RBP) regulates apoptosis in cancer. Moreover, epigenetic modifications, including DNA and RNA methylation and histone modifications, are also involved in H19-associated PCD regulation. In conclusion, we summarize the role of H19 signaling via PCD in cancer chemoresistance, highlighting the promising research significance of H19 as a therapeutic target. We hope that our study will contribute to a broader understanding of H19 in cancer development and treatment.
- 14 February 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-13
Open AccessLong noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer
Long noncoding RNAs (lncRNAs) are a group of noncoding RNAs with transcript lengths of >200 nucleotides. Mounting evidence suggests that lncRNAs are closely associated with tumorigenesis. LncRNA H19 (H19) was the first lncRNA to function as an oncogene in many malignant tumors. Apart from the established role of H19 in promoting cell growth, proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and metastasis, it has been recently discovered that H19 also inhibits programmed cell death (PCD) of cancer cells. In this review, we summarize the mechanisms by which H19 regulates PCD in cancer cells through various signaling pathways, molecular mechanisms, and epigenetic modifications. H19 regulates PCD through the Wnt/β-catenin pathway and the PI3K–Akt–mTOR pathway. It also acts as a competitive endogenous RNA (ceRNA) in PCD regulation. The interaction between H19 and RNA-binding proteins (RBP) regulates apoptosis in cancer. Moreover, epigenetic modifications, including DNA and RNA methylation and histone modifications, are also involved in H19-associated PCD regulation. In conclusion, we summarize the role of H19 signaling via PCD in cancer chemoresistance, highlighting the promising research significance of H19 as a therapeutic target. We hope that our study will contribute to a broader understanding of H19 in cancer development and treatment.